KalVista Pharmaceuticals

38 articles with KalVista Pharmaceuticals

• KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

  6/4/2019

  KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study

• KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference - May 30, 2019

  5/30/2019

  KalVista Pharmaceuticals, Inc. announced that it will present at the Jefferies Healthcare Conference on Thursday, June 6, 2019, at 4:00 p.m. ET in New York, NY.

• KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop

  5/28/2019

  KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE

• KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

  5/20/2019

  Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented

• KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

  4/30/2019

  Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice

• KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

  4/22/2019

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that Daniel Soland has been appointed to its Board of Directors effective immediately.

• KalVista Pharmaceuticals to Present at Needham Healthcare Conference

  4/3/2019

  KalVista Pharmaceuticals, Inc. announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, at 2:10 p.m. ET in New York, NY.

• KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer

  3/27/2019

  KalVista Pharmaceuticals, Inc. announced the promotion of Ben Palleiko to Chief Business Officer in addition to his current role as Chief Financial Officer, effective immediately.

• KalVista Pharmaceuticals Reports Fiscal Third Quarter Results - March 14, 2019

  3/14/2019

  KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.

• KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019

  2/25/2019

  KalVista Pharmaceuticals, Inc. announced data from a poster presentation given Saturday, February 23, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA.

• KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors

  2/1/2019

  KalVista Pharmaceuticals, Inc. announced that Brian Pereira has been appointed to its Board of Directors effective February 1, 2019.

• KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans

  1/4/2019

  KVD900 Phase 2 HAE Trial Data Expected in 2019

• KalVista Pharmaceuticals Reports Fiscal Second Quarter 2018 Results

  12/14/2018

  KVD900 Enlarged Phase 2 Trial on Track for Potential On-Demand Treatment of Attacks in Patients with Hereditary Angioedema

• KalVista Pharmaceuticals Provides Clinical Update on KVD900

  11/12/2018

  Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019

• KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

  11/6/2018

  KalVista Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences.

• KalVista Pharmaceuticals to Present at 2018 Cantor Global Healthcare Conference

  9/25/2018

  KalVista Pharmaceuticals, Inc. today announced that it will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 8:00 a.m. ET in New York, NY.

• KalVista Pharmaceuticals Reports Fiscal First Quarter 2018 Results

  9/14/2018

  KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema

• KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  9/6/2018

  The gross proceeds to KalVista from the offering are expected to be approximately $68.0 million

• KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

  8/7/2018

  The 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 3:40 p.m. ET in New York, NY.

• KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

  7/31/2018

  KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE)